Precigen, Inc.

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. At the Annual Meeting of Stockholders of Precigen, Inc. (the “Company”) held on June 18, 2026 (the “2026 Annual Meeting”), the Company’s stockholders approved an amendment to the Precigen, Inc. 2023 Omnibus Incentive Plan, as amended (the “2023 Plan”), to increase the number of shares of common stock available for issuance thereunder by 7 million (the “2023 Plan Amendment No. 3”). The approval of the 2023 Plan Amendment No. 3 had been previously approved by the Company’s Board of Directors (the “Board”), subject to stockholder approval. The 2023 Plan Amendment No. 3 amends the 2023 Plan, which was previously approved by the Company’s stockholders on June 8, 2023, and subsequently amended by the Company’s stockholders on July 5, 2024 and June 26, 2025. The principal features of the 2023 Plan Amendment No. 3 are described in detail under “Proposal 4 - Approval of an Amendment to the Precigen, Inc. 2023 Omnibus Incentive Plan, as Amended (the “2023 Plan”)” of the Company’s Definitive Proxy Statement on Schedule 14A for the 2026 Annual Meeting filed by the Company with the Securities and Exchange Commission on April 30, 2026 (the “Proxy Statement”). The full text of the 2023 Plan Amendment No. 3 is attached as Annex A to the Proxy Statement.

Item 5.07. Submission of Matters to a Vote of Security Holders. At the 2026 Annual Meeting, the Company’s stockholders (i) elected each of the persons listed below as a director for a one-year term, (ii) ratified the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026, (iii) approved a non-binding advisory resolution approving the compensation of the named executive officers, and (iv) approved the 2023 Plan Amendment No. 3. Proposal 1 - Election of directors. For Against Abstain Broker Non-Votes ─────────────────────────────────────────────────────────────────────────────────────────── Randal Kirk 207,060,147 5,072,069 154,634 61,452,809 Nancy Howell Agee 206,723,562 4,245,863 1,317,425 61,452,809 Cesar Alvarez 198,441,890 12,508,463 1,336,497 61,452,809 Steven Frank 205,741,016 5,182,858 1,362,976 61,452,809 Vinita Gupta 153,104,242 57,856,824 1,325,784 61,452,809 Fred Hassan 206,611,453 4,378,940 1,296,457 61,452,809 Jeffrey Kindler 206,614,657 4,373,888 1,298,305 61,452,809 Helen Sabzevari 210,626,763 1,532,092 127,995 61,452,809 James Turley 206,342,088 4,646,207 1,298,555 61,452,809 Proposal 2 - Ratification of the Appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. For Against Abstain ───────────────────────────────────────── 272,813,907 253,969 671,783 Proposal 3 - Non-binding advisory resolution approving the compensation of the named executive officers. For Against Abstain Broker Non-Votes ─────────────────────────────────────────────────────────────────── 208,241,739 2,790,879 1,254,232 61,452,809 Proposal 4 - Approval of an amendment to the Precigen, Inc. 2023 Omnibus Incentive Plan, as amended, to increase the number of shares of common stock which may be subject to awards thereunder by 7 million. For Against Abstain Broker Non-Votes ───────────────────────────────────────────────────────────────── 207,056,264 4,996,260 234,326 61,452,809